生物制药公司Akebia Therapeutics（股票代码：AKBA）今日盘中股价暴跌31.34%，引发市场广泛关注。这一显著跌幅主要源于公司宣布的新股发行计划，引发了投资者对潜在股权稀释的强烈担忧。
据报道，Akebia Therapeutics已宣布以每股2美元的价格发行2500万股新股，总融资额为5000万美元。这一发行价较公司上一交易日收盘价2.84美元大幅折价29.6%。公司表示，此次融资所得将用于营运资金和一般企业用途，包括其产品和候选药物的研发和商业活动。
值得注意的是，在此消息公布之前，AKBA股价曾连续四个交易日上涨，累计涨幅高达68%。然而，这一大幅折价的增发计划严重打击了投资者信心。尽管公司上周曾预计其贫血药物Vafseo在第一季度将实现1000万至1100万美元的净产品收入，显示了公司核心产品的市场潜力，但新股发行计划的负面影响暂时盖过了这一利好因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.